Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Announce Earnings of -$0.87 Per Share
Analysts predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will report ($0.87) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($1.06). Global Blood Therapeutics reported earnings of ($0.78) per share in the same quarter last year, which indicates a negative year over year growth rate of 11.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($3.58) per share for the current fiscal year, with EPS estimates ranging from ($4.14) to ($0.87). For the next fiscal year, analysts expect that the company will post earnings of ($2.87) per share, with EPS estimates ranging from ($4.25) to $0.26. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.07.
Global Blood Therapeutics stock traded down $1.43 during midday trading on Tuesday, reaching $55.81. 1,226,493 shares of the stock traded hands, compared to its average volume of 663,156. The company has a quick ratio of 14.51, a current ratio of 14.51 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of -16.37 and a beta of 1.77. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $63.00.
Hedge funds and other institutional investors have recently modified their holdings of the business. Truvestments Capital LLC bought a new stake in shares of Global Blood Therapeutics in the 1st quarter valued at approximately $33,000. Kore Private Wealth LLC purchased a new position in shares of Global Blood Therapeutics during the 1st quarter valued at about $53,000. Lindbrook Capital LLC purchased a new position in shares of Global Blood Therapeutics during the 4th quarter valued at about $55,000. Strs Ohio purchased a new position in shares of Global Blood Therapeutics during the 4th quarter valued at about $65,000. Finally, Bank of Montreal Can raised its holdings in shares of Global Blood Therapeutics by 61.9% during the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock valued at $65,000 after buying an additional 605 shares in the last quarter.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
See Also: What is the Producer Price Index (PPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.